March 30, 2026
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, review the rapid evolution of frontline therapy for EGFR-mutant advanced non–small cell lung cancer (NSCLC). Villanueva highlights the impact of the FLAURA trial (NCT02296125) in establishing osimertinib (Tagrisso) as the standard of care, while both experts discuss how newer combination strategies, including osimertinib plus chemotherapy and amivantamab-vmjw (Rybrevant)-based regimens, have demonstrated improvements in progression-free and overall survival, reshaping the treatment landscape.
Related Posts
Interpreting Overall Survival Data With Combination Strategies in EGFR-Mutant NSCLC
Rethinking High-Risk EGFR-Mutant NSCLC
Integrating ctDNA Into Frontline Decision-Making in EGFR-Mutant NSCLC
Sequencing Strategies After Frontline Intensification in EGFR-Mutant NSCLC
The Emerging Role of ADCs in EGFR-Mutant NSCLC
